Jubilant Pharmova Ltd
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
- Market Cap ₹ 17,393 Cr.
- Current Price ₹ 1,092
- High / Low ₹ 1,310 / 532
- Stock P/E 418
- Book Value ₹ 144
- Dividend Yield 0.46 %
- ROCE 2.63 %
- ROE 1.35 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 171%
Cons
- Stock is trading at 7.57 times its book value
- The company has delivered a poor sales growth of -25.6% over past five years.
- Company has a low return on equity of 2.91% over last 3 years.
- Earnings include an other income of Rs.121 Cr.
- Working capital days have increased from 83.2 days to 137 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Part of BSE 250 SmallCap Index Nifty Smallcap 250 BSE 400 MidSmallCap Index BSE Healthcare Nifty 500
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3,142 | 3,666 | 3,172 | 2,656 | 2,491 | 3,306 | 3,439 | 3,140 | 2,710 | 88 | 810 | 785 | 713 | |
2,650 | 3,076 | 2,890 | 2,344 | 2,173 | 2,765 | 3,112 | 2,765 | 2,282 | 95 | 807 | 767 | 707 | |
Operating Profit | 492 | 590 | 282 | 312 | 318 | 541 | 326 | 375 | 427 | -7 | 3 | 18 | 7 |
OPM % | 16% | 16% | 9% | 12% | 13% | 16% | 9% | 12% | 16% | -8% | 0% | 2% | 1% |
-90 | -198 | 305 | 62 | 52 | 45 | 72 | 168 | 48 | 126 | 138 | 102 | 121 | |
Interest | 263 | 285 | 233 | 201 | 174 | 135 | 129 | 136 | 102 | 31 | 18 | 30 | 32 |
Depreciation | 152 | 175 | 107 | 87 | 81 | 83 | 86 | 107 | 100 | 6 | 43 | 48 | 51 |
Profit before tax | -13 | -68 | 246 | 86 | 115 | 368 | 183 | 299 | 273 | 82 | 79 | 42 | 45 |
Tax % | 238% | -101% | 17% | 16% | 31% | 28% | 20% | -7% | 21% | 5% | 37% | 24% | |
-43 | 1 | 205 | 73 | 79 | 263 | 148 | 321 | 214 | 78 | 50 | 32 | 30 | |
EPS in Rs | -2.72 | 0.05 | 12.88 | 4.58 | 4.97 | 16.54 | 9.27 | 20.16 | 13.46 | 4.93 | 3.13 | 1.98 | 1.91 |
Dividend Payout % | -110% | 5,652% | 23% | 65% | 60% | 18% | 49% | 25% | 37% | 101% | 159% | 252% |
Compounded Sales Growth | |
---|---|
10 Years: | -14% |
5 Years: | -26% |
3 Years: | -34% |
TTM: | -9% |
Compounded Profit Growth | |
---|---|
10 Years: | -18% |
5 Years: | -27% |
3 Years: | -47% |
TTM: | 218% |
Stock Price CAGR | |
---|---|
10 Years: | 23% |
5 Years: | 18% |
3 Years: | 25% |
1 Year: | 87% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 7% |
3 Years: | 3% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Reserves | 1,828 | 1,717 | 1,929 | 1,998 | 2,027 | 2,233 | 2,324 | 2,591 | 1,267 | 1,266 | 2,399 | 2,359 | 2,283 |
3,263 | 3,314 | 2,279 | 1,808 | 1,698 | 1,424 | 1,702 | 2,013 | 504 | 507 | 346 | 380 | 349 | |
1,385 | 1,604 | 963 | 507 | 651 | 951 | 821 | 814 | 58 | 41 | 248 | 237 | 244 | |
Total Liabilities | 6,492 | 6,651 | 5,188 | 4,329 | 4,391 | 4,625 | 4,864 | 5,433 | 1,845 | 1,829 | 3,008 | 2,992 | 2,892 |
2,185 | 2,151 | 1,446 | 1,415 | 1,421 | 1,438 | 1,491 | 1,865 | 127 | 124 | 687 | 711 | 710 | |
CWIP | 213 | 242 | 20 | 36 | 65 | 115 | 284 | 59 | 0 | 0 | 47 | 37 | 26 |
Investments | 1,979 | 2,006 | 1,766 | 1,709 | 1,710 | 1,706 | 1,764 | 1,764 | 1,646 | 1,646 | 1,657 | 1,657 | 1,657 |
2,114 | 2,251 | 1,955 | 1,169 | 1,195 | 1,365 | 1,325 | 1,746 | 71 | 60 | 617 | 587 | 499 | |
Total Assets | 6,492 | 6,651 | 5,188 | 4,329 | 4,391 | 4,625 | 4,864 | 5,433 | 1,845 | 1,829 | 3,008 | 2,992 | 2,892 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
827 | 549 | 286 | 164 | 419 | 558 | 182 | 317 | 608 | -4 | -65 | 143 | |
-399 | -194 | 1,319 | 522 | -43 | -127 | -285 | -198 | 178 | 93 | 31 | -40 | |
-446 | -361 | -1,647 | -784 | -338 | -470 | 85 | -41 | -782 | -107 | 22 | -78 | |
Net Cash Flow | -18 | -6 | -42 | -98 | 38 | -40 | -18 | 78 | 5 | -18 | -12 | 25 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 46 | 53 | 37 | 47 | 57 | 54 | 51 | 49 | 0 | 88 | 85 | 90 |
Inventory Days | 132 | 135 | 97 | 119 | 127 | 120 | 87 | 142 | 0 | 276 | 258 | |
Days Payable | 111 | 110 | 96 | 91 | 136 | 154 | 106 | 134 | 145 | 152 | ||
Cash Conversion Cycle | 67 | 77 | 38 | 75 | 47 | 21 | 32 | 58 | 0 | 88 | 216 | 196 |
Working Capital Days | 53 | -51 | 63 | 44 | 48 | 27 | 44 | 83 | -2 | -42 | 154 | 137 |
ROCE % | 8% | 9% | 6% | 7% | 7% | 14% | 8% | 10% | 12% | 6% | 4% | 3% |
Documents
Announcements
- Closure of Trading Window 24 Dec
-
Announcement under Regulation 30 (LODR)-Credit Rating
10 Dec - India Ratings affirms IND AA+ rating for Jubilant Pharmova.
-
Deferment Of Investor/ Analysts Meeting
5 Nov 2024 - Deferment of Investor and Analyst Meet 2024.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 Oct 2024 - Copy of Newspaper publication for the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
25 Oct 2024 - Jubilant Pharmova announces Q2 & H1 FY25 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Oct 2024TranscriptNotesPPT
-
Jul 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Oct 2023TranscriptNotesPPT
-
Jul 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Mar 2022TranscriptNotesPPT
-
Jan 2022TranscriptPPT
-
Jul 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Oct 2017TranscriptPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Jul 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Jan 2016TranscriptPPT
Business Segments & Revenue Contribution 9MFY24[1][2]
a) Radiopharma (~44%): Radiopharmaceuticals (including radiopharmacies)The company is the #3 radiopharmaceutical manufacturer in the US and has the #2 network in the US with 46 radiopharmacies. In 9MFY24, sale of Mertiatide, Sulfur colloid) and Ruby-Fill did very well. RUBY-FILL is a cardiac imaging product. Company plans to maintain its leadership position in North America.[3]